ACAD Insider Activity: Schneyer PSU Vesting and Tax-Related Sale
Rhea-AI Filing Summary
Mark C. Schneyer, EVP & Chief Financial Officer of ACADIA Pharmaceuticals (ACAD), reported two transactions in September 2025. On 09/12/2025 he acquired 6,815 shares of common stock upon vesting of performance stock units granted May 1, 2023, representing an incremental 25% of target and bringing total PSU vesting to 75% of target. Following that acquisition his beneficial ownership rose to 46,945 shares.
On 09/15/2025 he sold 3,498 shares at $23.65 per share to satisfy withholding taxes and related tax items associated with the PSU vesting, leaving him with 43,447 shares beneficially owned. The sale was reported as a mandatory sale intended to comply with Rule 10b5-1(c) provisions.
Positive
- Executive share acquisition through PSU vesting aligns management compensation with company performance metrics.
- Use of Rule 10b5-1(c) framework for tax-related sales reduces concerns about opportunistic insider trading.
Negative
- Mandatory sale of 3,498 shares reduced the reporting person’s holdings, partially offsetting the vested award.
- Vesting only at 75% of target to date, indicating remaining performance units are still outstanding and unvested.
Insights
TL;DR: Routine insider vesting and tax-related withholding sale; alignment with shareholders preserved.
The filing documents standard executive compensation vesting and an accompanying mandatory sell-to-cover to meet tax obligations. The acquisition of 6,815 shares through vested performance stock units signals compensation realization rather than a market-timed purchase. The subsequent sale of 3,498 shares to cover tax withholding is a common administrative action and was executed under a stated Rule 10b5-1(c) framework, which aims to reduce questions about selective trading. This disclosure is procedural and does not by itself indicate a governance concern.
TL;DR: Modest net insider increase; transactions are small relative to typical market-moving events.
Net change reduces reported holdings from 46,945 to 43,447 shares after a $23.65 per share sale of 3,498 shares. The $0 acquisition price reflects vesting rather than a purchase. The trades are unlikely to be materially impactful to ACAD stock or alter valuation metrics given the small share counts disclosed. The Form 4 is informative about executive compensation realization timing but not a material operational update.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 3,498 | $23.65 | $83K |
| Grant/Award | Common Stock | 6,815 | $0.00 | -- |
Footnotes (1)
- Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at incremental 25% of target. Together with the vesting on August 16, 2024, the performance stock units have vested at 75% of target. The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
